<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106310</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1 13th Aug 2019</org_study_id>
    <nct_id>NCT04106310</nct_id>
  </id_info>
  <brief_title>Theranova vs High-flux HD Comparison</brief_title>
  <official_title>The Comparison of Expanded Dialysis With Theranova Dialyzer With Conventional High-flux Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research proposal of an investigator-initiated clinical study aims to examine the impact&#xD;
      of uremic toxin removal afforded by middle cut-off (MCO) dialysis on clinical parameters and&#xD;
      surrogate biomarkers pertinent to nutritional, systemic and vascular complications in&#xD;
      dialysis patients. The primary research goal is to evaluate the outcomes indicative of&#xD;
      nutritional status (as measured by body mass index, body composition monitoring, albumin,&#xD;
      clinical assessments such as subjective global assessment, etc.) and parameters relevant to&#xD;
      pathophysiological processes in uremia focusing on inflammation and cardiovascular risks. The&#xD;
      secondary research aims are to examine dialysis efficacy between MCO dialysis and&#xD;
      conventional hemodialysis (CHD). Specifically, dialysis efficacy will be determined by within&#xD;
      and between subject differences in baseline versus short term (6 months) and long term (12&#xD;
      months) effects of MCO dialysis and CHD in:&#xD;
&#xD;
        1. Removal of small molecules (e.g. urea), middle molecules (Beta-2 microglobulin,&#xD;
           Phosphate and Creatinine) and protein bound solutes&#xD;
&#xD;
        2. Markers of inflammation, ossification and fibrosis&#xD;
&#xD;
        3. Uremia associated epigenetic modification The investigators hypothesize superiority of&#xD;
           nutritional parameters in patients undergoing MCO dialysis compared with patients on&#xD;
           CHD. The investigators plan to randomize 60 patients to either MCO dialysis or CHD at&#xD;
           two hemodialysis units in Hong Kong.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accumulation of uremic toxins is associated morbidity and mortality in patients with&#xD;
      end-stage renal disease, but the pathogenic mechanisms how they lead to various clinical&#xD;
      complications remain elusive. Conventional hemodialysis is effective in removing small&#xD;
      molecular solutes (in the range of 50-15,000 Da), but the removal of protein-bound and middle&#xD;
      to larger molecular toxins (up to 50,000 Da) remains unsatisfactory even with augmented&#xD;
      hemodialysis frequency or duration. The notion that dialysis adequacy is no longer a simple&#xD;
      quantitative measure of small molecular removal has led to the clinical application of&#xD;
      intensive hemodialysis and the search for novel strategies to reduce uremic toxin burden.&#xD;
&#xD;
      Recently, a new class of membrane with molecular weight cut off (MWCO) close to the molecular&#xD;
      weight of albumin was introduced. The focus of this new therapy, known as expanded dialysis&#xD;
      using the medium cut off (MCO) dialysis membrane, is to provide the potential for more&#xD;
      efficient removal of middle molecules and protein bound uremic toxins without excessive loss&#xD;
      of albumin. To date, MCO dialysis has been associated with a reduction in transcription of&#xD;
      pro-inflammatory cytokines (i.e. interleukin 6 and tumor necrosis factor-Î±) and middle&#xD;
      molecules especially free lambda light chains.&#xD;
&#xD;
      Protein-energy wasting and cardiovascular diseases are prevalent in chronic kidney disease&#xD;
      and is related to inflammation and increased mortality. Despite growing data on the clearance&#xD;
      of individual uremic toxins and biochemical parameters, the impact of MCO dialysis on&#xD;
      clinical outcomes and mechanistic parameters related to nutrition and inflammation remains to&#xD;
      be investigated.&#xD;
&#xD;
      The objective of the study is to compare MCO dialysis with conventional high-flux HD, on&#xD;
      nutritional parameters, inflammation and cardiovascular biomarkers and related clinical&#xD;
      outcomes.&#xD;
&#xD;
      Since twice-weekly HD is commonly practiced in Hong Kong, this study provides a distinct&#xD;
      opportunity to investigate whether MCO dialysis might be particularly advantageous in&#xD;
      patients receiving a relatively lower dialysis dose through the removal of a broader spectrum&#xD;
      of uremic toxins.&#xD;
&#xD;
      The investigators hypothesize that MCO dialysis with Theranova Dialyzer (HDx) improves&#xD;
      parameters related to nutrition and inflammation compared with high-flux HD.&#xD;
&#xD;
      This will be a prospective single-blinded, randomized, controlled trial with stable HD&#xD;
      patients randomized at 1:1 ratio to either one of the following - A. to continue with HD&#xD;
      using the same high-flux dialyzer as in the previous 6 weeks (high-flux HD arm) B. change to&#xD;
      HDx using Theranova Dialyzer (MCO dialysis arm)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The dialyzer used will be covered</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>lean tissue index</measure>
    <time_frame>12 months</time_frame>
    <description>measured by Body Composition Monitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>12 months</time_frame>
    <description>measured by weight (in kilograms) divided by the square of heights (in meters)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>asymmetrical dimethylarginine</measure>
    <time_frame>12 months</time_frame>
    <description>endogenous inhibitor of nitric oxide synthase, one of the cardiovascular biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibroblast growth factor 23</measure>
    <time_frame>12 months</time_frame>
    <description>biomarker for bone turnover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Klotho</measure>
    <time_frame>12 months</time_frame>
    <description>biomarker for atherosclerosis and bone turnover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kt/V urea</measure>
    <time_frame>12 months</time_frame>
    <description>measurement of clearance of urea by hemodialysis therapy, a marker for adequacy of dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beta-2 microglobulin</measure>
    <time_frame>12 months</time_frame>
    <description>middle size uremic toxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pentraxin-3</measure>
    <time_frame>12 months</time_frame>
    <description>middle to large molecular size uremic toxin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>soluble endothelial protein C receptor</measure>
    <time_frame>12 months</time_frame>
    <description>a marker for endothelial dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>soluble thrombomodulin</measure>
    <time_frame>12 months</time_frame>
    <description>a marker for endothelial dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobulin</measure>
    <time_frame>12 months</time_frame>
    <description>indication of anemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-sensitive C reactive protein</measure>
    <time_frame>12 months</time_frame>
    <description>marker for inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin 6</measure>
    <time_frame>12 months</time_frame>
    <description>marker for inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor necrosis factor alpha</measure>
    <time_frame>12 months</time_frame>
    <description>marker for inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>albumin</measure>
    <time_frame>12 months</time_frame>
    <description>marker for nutritional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>12 months</time_frame>
    <description>marker for nutritional status and appetite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adiponectin</measure>
    <time_frame>12 months</time_frame>
    <description>nutritional marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphate</measure>
    <time_frame>12 months</time_frame>
    <description>small size uremic waste produce</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low-density lipoprotein</measure>
    <time_frame>12 months</time_frame>
    <description>reflects lipid control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-density lipoprotein</measure>
    <time_frame>12 months</time_frame>
    <description>reflects lipid control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglyceride</measure>
    <time_frame>12 months</time_frame>
    <description>reflects lipid control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malnutrition-Inflammation Score</measure>
    <time_frame>12 months</time_frame>
    <description>a measurement scale reflecting nutritional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Global Assesment questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>a measurement scale reflecting nutritional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fat tissue index</measure>
    <time_frame>12 months</time_frame>
    <description>nutritional marker measured by Body Composition Monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>admission rate due to cardiovascular events</measure>
    <time_frame>12 months</time_frame>
    <description>number of admisisons due to cardiovascular events during the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>admission rate due to infection</measure>
    <time_frame>12 months</time_frame>
    <description>number of admissions due to infection during the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>12 months</time_frame>
    <description>number of deaths during the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-D itch scale</measure>
    <time_frame>12 months</time_frame>
    <description>Symptomatology scale to measure itchiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale for itchiness</measure>
    <time_frame>12 months</time_frame>
    <description>Symptomatology scale to measure itchiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) score</measure>
    <time_frame>12 months</time_frame>
    <description>measurement scale for appetite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale for appetite</measure>
    <time_frame>12 months</time_frame>
    <description>measurement scale for appetite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postdialysis recovery time</measure>
    <time_frame>12 months</time_frame>
    <description>number of time required to feel well after receiving a hemodialysis session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported sleep quality</measure>
    <time_frame>12 months</time_frame>
    <description>scale to rate the quality of sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hong Kong Montreal Cognitive Assessment</measure>
    <time_frame>12 months</time_frame>
    <description>measurement of cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KDQOLSFTMv1.3 questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>quality of life assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA methylation analysis of TRPV1 gene</measure>
    <time_frame>12 months</time_frame>
    <description>epigenetics modification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA methylation analysis of LY96 gene</measure>
    <time_frame>12 months</time_frame>
    <description>epigenetics modificaiton</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA methylation analysis of IFNGR1 gene</measure>
    <time_frame>12 months</time_frame>
    <description>epigenetics modifications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <arm_group>
    <arm_group_label>Theranova</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be receiving hemodialysis using Theranova dialyzer. The other hemodialysis parameters are kept the same.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-flux</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be receiving hemodialysis using a high-flux dialyzer. The other hemodialysis parameters are kept the same</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-flux dialyzer</intervention_name>
    <description>a dialyzer meeting the definition of high-flux</description>
    <arm_group_label>High-flux</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Theranova dialyzer</intervention_name>
    <description>a middle cut-off dialyzer</description>
    <arm_group_label>Theranova</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients age greater than 18 years old&#xD;
&#xD;
          -  end-stage renal failure on two- or three-times per week high-flux HD for more than 90&#xD;
             days&#xD;
&#xD;
          -  mean spKt/Vurea &gt;1.2 per session (for 3 dialysis sessions per week) or spKt/Vurea &gt;1.8&#xD;
             per session (for 2 dialysis sessions per week)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active malignancy&#xD;
&#xD;
          -  unable to give informed consent or complete questionnaires&#xD;
&#xD;
          -  unstable clinical condition defined as significant clinical event requiring&#xD;
             hospitalization in the past 90 days&#xD;
&#xD;
          -  unreliable vascular access&#xD;
&#xD;
          -  unable to achieve HD blood flow &gt;150ml/min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maggie Ming Yee Mok, MBBS, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Medicine, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tung Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Mok Ming Yee</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

